share_log

BRIEF-Selecta Biosciences And Ginkgo Bioworks Holdings Inc Announce Partnership To Advance Treatments For Orphan And Rare Diseases

reuters ·  2021/10/26 08:30

Oct 26 (Reuters) - Ginkgo Bioworks Holdings Inc DNA.N :

* SELECTA BIOSCIENCES AND GINKGO BIOWORKS ANNOUNCE PARTNERSHIP TO ADVANCE TREATMENTS FOR ORPHAN AND RARE DISEASES

* SELECTA BIOSCIENCES - LEVERAGING GINKGO'S CELL PROGRAMMING PLATFORM & CO'S IMMTOR PLATFORM TO CREATE POTENTIALLY TRANSFORMATIVE ENZYMATIC THERAPIES

* SELECTA BIOSCIENCES - GAINS RIGHTS TO DEVELOP, COMMERCIALIZE SELECT THERAPEUTIC ENZYMES FROM GINKGO'S ADVANCED ORGANISM ENGINEERING PLATFORM

* SELECTA BIOSCIENCES - GINKGO IS ELIGIBLE TO EARN CLINICAL AND COMMERCIAL MILESTONE PAYMENTS OF UP TO $85M IN CASH

* SELECTA BIOSCIENCES - GINKGO ELIGIBLE TO EARN UPFRONT RESEARCH & DEVELOPMENT FEES, MILESTONES, INCLUDING CERTAIN PAYMENTS IN FORM OF CO'S COMMON STOCK

Source text for Eikon: ID:nGNX7rtyW1 Further company coverage: DNA.N

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする